Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.
about
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.The present and future of withdrawal period calculations for milk in the European Union: focus on heterogeneous, nonmonotonic data.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive suTranslational Modeling of Drug-Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor.Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.Population pharmacokinetics of emtricitabine in HIV-1-infected adult patientsPopulation pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults.Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia.Tips and traps analyzing pediatric PK data.Evaluation of different tests based on observations for external model evaluation of population analyses.Population pharmacokinetics of nefopam in elderly, with or without renal impairment, and its link to treatment response.High variability in the exposure of baclofen in alcohol-dependent patients.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphomaPredictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermiaMoxifloxacin dosing in post-bariatric surgery patients.Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.Population pharmacokinetics of abacavir in pregnant women.Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensTowards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.Pharmacokinetics of oral fludrocortisone in septic shock.Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach.Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifenPopulation pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.Association between vancomycin trough concentration and area under the concentration-time curve in neonatesModified renal function in pregnancy: impact on emtricitabine pharmacokinetics.Population pharmacokinetics of deferiprone in healthy subjects.Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.Prediction of disease progression, treatment response and dropout in chronic obstructive pulmonary disease (COPD)Lopinavir/ritonavir population pharmacokinetics in neonates and infants.Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.Pharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected children
P2860
Q30499990-64A43FFE-50DF-4A48-BBEA-8DA4F68AB93AQ30844731-D2877427-9AEE-4FAE-8C21-31FA35E7B6BFQ31127244-AA3CB2D7-6C35-4543-B235-2ED5F5DCC2A8Q33415594-050B042F-9E44-4421-8994-845C5379093CQ33416659-37B866F3-45B9-44EA-B666-DCC6C19545C9Q33440695-3138530E-CF8D-437E-83D8-94D5C477A9ABQ33571417-B0B8F336-AF70-452D-A6FF-D448396BA44EQ33622825-6AB263E3-E56F-4878-A43A-B7D0D5C7FDBEQ33689718-A8548281-B7AF-4DF6-8E33-BD90A75FDAC1Q33708140-5CFA15D2-ACFE-41B3-8766-AB95DDC0A9C5Q33729768-EF0C13FE-FEC4-45EC-93FC-1A890E60251CQ33797950-B5747F4C-3854-4C5B-B9E5-7588D12E565CQ33812116-00C2B9B1-7C10-4C0F-9125-239C5FA62CEAQ33820152-67A391EF-5D77-4A12-B44D-8162C9A4C21FQ33869167-65002073-47DA-4C62-8FF7-2F8F6A1373E9Q33887993-3864CD92-0BF2-4C17-82FA-B202840386F3Q34038135-811EF5E8-7A3D-4AE2-803B-28C2D5D4D043Q34065294-F15227F0-3BB8-42D5-8DCE-44405EEF5D14Q34174899-066094F8-C560-4CF3-9ACF-CB88C7F02CB6Q34200271-51937ACA-036A-436E-9FA7-ED1218024FC9Q34209532-FBC4EF4F-689F-4D43-A6F3-75727CDA5798Q34209556-6A660E10-973A-4583-9E85-D94ED9DC196EQ34299084-D1F4DC52-B346-4D8C-8014-3472E43B81B0Q34328266-49496155-1BBC-4FB9-AB65-08E904F5AA0AQ34381321-AA6BF16F-B121-4E5D-88B9-D7E1841AF1B4Q34393200-AF92C29A-8C35-4BD3-845B-72E93EFC0E54Q34476089-1273E9E8-F2DB-40AD-8D56-C99FBC207658Q34534167-F9B67B70-4178-409E-8887-CE2A964400C5Q34570942-38FB8079-3612-4196-806D-0F5A9BFF04CEQ34571065-40CF928B-1CE6-4123-92CE-94757BFA3883Q34596303-CB0267A2-4CDC-4B01-95E1-C133967F82CBQ34596435-DCB796C8-BE9E-4F76-9927-308B82C96194Q34635554-3AB521EC-4B51-4A46-8B4B-63340BFDE123Q34635568-E612B7BE-9D2F-4F6B-B997-AFEE5A27C1ECQ34700914-C78A1CC8-E4CB-435E-B962-3A3E23FD87B8Q34895303-B811539D-A084-47F8-834E-4D3ABF99C76EQ34990277-962B9090-C05C-4E27-B8D8-4373296676E4Q34996974-29B030FF-9B35-418D-A3A2-64A89C520CB2Q35023731-A0332BB9-9BE4-408B-BA86-51854F5BE10EQ35191590-E832D023-AF88-4510-8742-C82E5A24EB46
P2860
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Computing normalised predictio ...... the npde add-on package for R.
@en
Computing normalised predictio ...... the npde add-on package for R.
@nl
type
label
Computing normalised predictio ...... the npde add-on package for R.
@en
Computing normalised predictio ...... the npde add-on package for R.
@nl
prefLabel
Computing normalised predictio ...... the npde add-on package for R.
@en
Computing normalised predictio ...... the npde add-on package for R.
@nl
P2093
P1476
Computing normalised predictio ...... the npde add-on package for R.
@en
P2093
Emmanuelle Comets
France Mentré
Karl Brendel
P304
P356
10.1016/J.CMPB.2007.12.002
P577
2008-01-22T00:00:00Z